Department of Gastroenterology and Endoscopy, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Dig Endosc. 2023 Jul;35(5):584-591. doi: 10.1111/den.14542. Epub 2023 Mar 30.
Endobiliary radiofrequency ablation (RFA) is an emerging technique in recent years for palliating malignant biliary strictures (MBS) unsuitable for surgical resection. To date, many clinical studies have shown good feasibility and safety of this therapy; but controversy exists on whether survival can be improved in patients with advanced MBS. A comprehensive review of the available literature demonstrates that RFA can effectively prolong the overall survival of extrahepatic cholangiocarcinoma (CCA) and ampullary cancer, especially in cases without distant metastasis. However, this topical therapy does not confer a survival benefit in patients with nonprimary bile duct malignancies, such as liver, gallbladder, or pancreatic cancers. Biliary RFA combined with systemic chemotherapy may have a synergistic effect on the outcome of inoperable CCA. Patients with locally advanced tumors rather than distant metastasis might benefit more from this combination therapy.
经内镜胆管内射频消融术(RFA)是近年来出现的一种姑息性治疗方法,适用于无法手术切除的恶性胆道狭窄(MBS)。迄今为止,许多临床研究表明该疗法具有良好的可行性和安全性;但对于晚期 MBS 患者的生存是否能够改善仍存在争议。对现有文献的综合回顾表明,RFA 可以有效延长肝外胆管癌(CCA)和壶腹癌患者的总生存期,特别是在无远处转移的情况下。然而,这种局部治疗并不能使非原发性胆管恶性肿瘤(如肝癌、胆囊癌或胰腺癌)患者受益。胆管 RFA 联合全身化疗可能对不可切除的 CCA 患者的预后有协同作用。局部晚期肿瘤而非远处转移的患者可能从这种联合治疗中获益更多。